JNJ vs TACT · P/E 17, rev $49.37B vs rev $28.4M
Johnson & Johnson (JNJ) versus TransAct Technologies Incorporated (TACT) — a side-by-side from cached financials, not a winner call.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
TransAct Technologies Incorporated (TACT) is a computer hardware company listed on US.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Latest reported TACT revenue for 2026-06-30 was $28.4M. Net income was $716.0K. Revenue was up 96.8% from 2026-03-31 to 2026-06-30. TACT currently screens at market cap $49.3M.
JNJ currently screens at market cap $375.37B and trailing P/E 17.4. TACT currently screens at market cap $49.3M.
Not investment advice. Open the JNJ and TACT stock pages for the full models.
Not investment advice.